Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Case Report
Case Series
Editorial
EDITORIAL BOARD 2026-20-1
Editorial I
Editorial II
Original Article
Review
Review Article
Systematic Review
Systematic Review and Meta-Analysis
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Case Report
Case Series
Editorial
EDITORIAL BOARD 2026-20-1
Editorial I
Editorial II
Original Article
Review
Review Article
Systematic Review
Systematic Review and Meta-Analysis
View/Download PDF

Translate this page into:

Original Article
2 (
2
); 17-25

Mutations in Epidermal Growth Factor Receptor Gene in Esophageal

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Disclaimer:
This article was originally published by Qassim University and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Activating mutations in Epidermal Growth Factor Receptor (EGFR) are common in lung adenocarcinoma of never smokers but are rare in other types of cancer. Here we have analysed mutations in exons 19 to 21 of EGFR and in exons 19 and 20 of the EGFR homolog HER2 in 54 cases of Esophageal Squamous Cell Carcinomas (ESCC) from patients recruited in Kashmir, India, a region of high incidence for this cancer. We report the detection of 3 mutations (6%) in the ATP-binding regulatory loops of the tyrosine kinase domain of EGFR (deletion 746-750, P753L, G719D). No mutation was found in HER2. This is the first report of activating EGFR mutations in ESCC, of the same type as those detected in lung adenocarcinoma of never-smokers. This suggests that a small proportion of ESCC patients in this high incidence area may benefit from treatment with EGFR tyrosine kinase inhibitors. Key words : EGFR, Mutations, Esophageal Cancer, Kashmir


Fulltext Views
272

PDF downloads
108
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections